微信公众号

官网二维码
中国癌症防治杂志

中国癌症防治杂志

• 论文 • 上一篇    下一篇

肺癌组织中RRM1表达对预测GP化疗方案疗效的作用

杨志坚;刘德森;陈发龙;陈军;覃思繁;林恩彤;   

  1. 广西医科大学研究生学院;广西医科大学肿瘤医院;
  • 收稿日期:2009-06-25 修回日期:2009-06-25 出版日期:2009-06-25 发布日期:2009-06-25

The effect of RRM1 expression in lung cancer tissues for predict chemotherapeutic effect of Gp

YANG Zhi-jian,LIU De-sen,CHEN Fa-long,et al.   

  1. (Department of Thoracic Surgery,Guangxi Cancer Institute,Nanning Guangxi 530021,China
  • Received:2009-06-25 Revised:2009-06-25 Online:2009-06-25 Published:2009-06-25

赞

被引次数

10

摘要： 目的探索核糖核苷还原酶亚单位RRM1在晚期非小细胞肺癌中的表达及其与吉西他滨化疗敏感性及效果的关系。方法采用免疫组化S-P法检测30例Ⅲ_b、Ⅳ期给予GP方案化疗(吉西他滨+顺铂)的非小细胞肺癌患者RRM1的表达情况,并分析其与化疗效果的关系。结果RRM1表达与性别、年龄、病理类型以及TNM分期差异均无统计学意义(P>0.05)。RRM1阳性表达组化疗有效率为12.5%,1年生存率为6.3%;RRM1阴性组化疗有效率为78.5%,1年生存率为64.3%,经统计学分析两组差异有统计学意义(P<0.05)。结论RRM1对GP方案化疗疗效及生存的预测呈负相关关系,可以作为预测晚期非小细胞肺癌GP方案化疗敏感性及生存预测的参考指标。

关键词: 晚期非小细胞肺癌, 免疫组织化学, RRM1, 个体化化疗

Abstract: Objective To explore the expression of ribonucleotide reductase subuint M1(RRM1) and its relation to drug-sensitivity and the therapeutic effect of GP(Gemcitabine and Cisplatin) in advanced non-small cell lung cancer(NSCLC) .Methods RRM1 expression was tested immunohistochemically on 30 cases ofⅢ_b orⅣstage NSCLC treated with GP.The relationship between RRM1 expression and the chemotherapeutic effect was analyzed.Results The differences of RRM1 expression between the comparable factors such as sex,age,tumor size,pathological type and TNM phase were not statistically significant (P>0.05).The effect rates of GP treatment in RRM1-positive group and RRM1-negative group were 12.5%and 78.5% respectively and the 1-year survival rates in these two groups were 6.3%and 64.3%respectively,the differences were statistically significant(P<0.05 ).Conclusions There are negative relativity between the level of RRM1 expression and chemotherapeutic effect of GP in NSCLC.Chemotherapeutic effect of GP would be predicted by testing level of RRM1 expression in advanced NSCLC,and the level of RRM1 expression would be helpful for selecting individualized chemotherapeutic program.

Key words: Advanced non-small cell lung cancer, Immunohistochemistry, RRM1, Individualized chemotherapy